Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDV4EP)

Drug Name

Adagrasib Drug Info

Synonyms

2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX-849; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Approved	[1]

Cross-matching ID

PubChem CID: 138611145
CAS Number: CAS 2326521-71-3
TTD Drug ID: DMDV4EP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting KRAS G12C mutant (KRAS G12C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotorasib	DMLSV74	Non-small-cell lung cancer	2C25	Approved	[3]
JDQ443	DMHI7CQ	Non-small-cell lung cancer	2C25	Phase 3	[4]
LY3499446	DMA1CSR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
RG6330	DMSX5NJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
JNJ-74699157	DMY7CW1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
KRAS G12C mutant (KRAS G12C)	TT3LH46	RASK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216340.
2	Clinical pipeline report, company report or official report of Mirati Therapeutics.
3	Clinical pipeline report, company report or official report of Amgen.
4	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
5	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
6	Clinical pipeline report, company report or official report of Roche.